Lataa...
Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
The treatment landscape of hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer has been modernized by the identification of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. Because the majority of HR+ breast cancers will develop res...
Tallennettuna:
| Julkaisussa: | J Adv Pract Oncol |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Harborside Press LLC
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7844194/ https://ncbi.nlm.nih.gov/pubmed/33552665 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2021.12.1.8 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|